Description
Odetiglucan is an investigational medication currently being studied in clinical trials for certain types of metastatic colorectal cancer, specifically those that have spread mainly to the liver. It is being tested in combination with pembrolizumab, an immunotherapy drug. The goal of these trials is to see if this combination is safe and effective for patients whose cancer has not responded well to standard treatments. Odetiglucan is being studied in patients whose tumors do not have certain common mutations (BRAF, EGFR, KRAS, NRAS) and are MSI-H (microsatellite instability-high). It is important to note that odetiglucan is not yet approved for use in colorectal cancer and is only available as part of a clinical trial.
Mechanism of Action
Odetiglucan is a type of medication that is currently being studied. The specific way it works (its mechanism of action) is still being investigated in clinical trials. It is thought to potentially affect the tumor microenvironment or interact with the immune system, but the exact molecular target or process is not yet fully defined.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.